{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T17:06:37Z","timestamp":1781024797706,"version":"3.54.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.jacl.2018.04.007","type":"journal-article","created":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T18:22:12Z","timestamp":1524766932000},"page":"999-1007","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Trends in high-intensity statin use and low-density lipoprotein cholesterol control among patients enrolled in a clinical pharmacy cardiac risk service"],"prefix":"10.1016","volume":"12","author":[{"suffix":"Jr.","given":"Donald G.","family":"Lamprecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan B.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri N.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari L.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2018.04.007_bib1","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart disease and stroke statistics\u20142017 update: a report from the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2018.04.007_bib2","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2018.04.007_bib3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacl.2014.07.007","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 \u2013 executive summary","volume":"8","author":"Jacobson","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2018.04.007_bib4","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","volume":"70","author":"Lloyd-Jones","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2018.04.007_bib5","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2018.04.007_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/1060028015608199","article-title":"Evaluation of statin prescribing for secondary prevention in primary care following new guideline recommendations","volume":"50","author":"Zupec","year":"2016","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jacl.2018.04.007_bib7","doi-asserted-by":"crossref","first-page":"901","DOI":"10.18553\/jmcp.2016.22.8.901","article-title":"Impact of the 2013 cholesterol guideline on patterns of lipid-lowering treatment in patients with atherosclerotic cardiovascular disease or diabetes after 1 year","volume":"22","author":"Tran","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jacl.2018.04.007_bib8","doi-asserted-by":"crossref","first-page":"892","DOI":"10.18553\/jmcp.2016.22.8.892","article-title":"Antihyperlipidemic medication treatment patterns and statin adherence among patients with ASCVD in a managed care plan after release of the 2013 ACC\/AHA guideline on the treatment of blood cholesterol","volume":"22","author":"Bellows","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jacl.2018.04.007_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jamacardio.2016.4052","article-title":"Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease","volume":"2","author":"Rodriguez","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2018.04.007_bib10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1001\/jamacardio.2016.5922","article-title":"Adoption of the 2013 American College of Cardiology\/American Heart Association cholesterol management guideline in cardiology practices nationwide","volume":"2","author":"Pokharel","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2018.04.007_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.116.004909","article-title":"Effect of 2013 ACC\/AHA blood cholesterol guidelines on statin treatment patterns and low-density lipoprotein cholesterol in atherosclerotic cardiovascular disease patients","volume":"6","author":"Okerson","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.jacl.2018.04.007_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2146\/ajhp060022","article-title":"Clinical pharmacy cardiac risk service for managing patients with coronary artery disease in a health maintenance organization","volume":"64","author":"Sandhoff","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jacl.2018.04.007_bib13","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.2146\/ajhp150781","article-title":"Pharmacist prescribing practices in a clinical pharmacy cardiac risk service","volume":"73","author":"Todd","year":"2016","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jacl.2018.04.007_bib14","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/00005650-199508000-00004","article-title":"A chronic disease score with empirically derived weights","volume":"33","author":"Clark","year":"1995","journal-title":"Med Care"},{"key":"10.1016\/j.jacl.2018.04.007_bib15","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/aje\/kwr183","article-title":"Performance of the modified Poisson regression approach for estimating relative risks from clustered prospective data","volume":"174","author":"Yelland","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jacl.2018.04.007_bib16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ahj.2016.09.007","article-title":"Use of high-intensity statins for patients with atherosclerotic cardiovascular disease in the Veterans Affairs Health System: practice impact of the new cholesterol guidelines","volume":"182","author":"Rodriguez","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2018.04.007_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2016.4700","article-title":"National trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the medical expenditure panel survey","volume":"2","author":"Salami","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2018.04.007_bib18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/jamacardio.2016.6007","article-title":"Trends in the use of moderate-intensity to high-intensity statin and nonstatin lipid-lowering therapy: turning off the faucet is much more valuable than mopping up the floor","volume":"2","author":"Blumenthal","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2018.04.007_bib19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2147\/TCRM.S1458","article-title":"Factors affecting therapeutic compliance: a review from the patient's perspective","volume":"4","author":"Jin","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jacl.2018.04.007_bib20","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4065\/mcp.2010.0575","article-title":"Medication adherence: WHO cares?","volume":"86","author":"Brown","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacl.2018.04.007_bib21","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2015.09.025","article-title":"The role of the clinical pharmacist in the care of patients with cardiovascular disease","volume":"66","author":"Dunn","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2018.04.007_bib22","doi-asserted-by":"crossref","first-page":"914.e5","DOI":"10.1016\/j.amjmed.2015.02.013","article-title":"The new lipid guidelines: what do primary care clinicians think?","volume":"128","author":"Jame","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.jacl.2018.04.007_bib23","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jacl.2015.11.002","article-title":"Provider understanding of the 2013 ACC\/AHA cholesterol guideline","volume":"10","author":"Virani","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2018.04.007_bib24","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1016\/j.jacc.2014.02.578","article-title":"2013 ACC\/AHA cholesterol treatment guideline: what was done well and what could be done better?","volume":"63","author":"Martin","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2018.04.007_bib25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3949\/ccjm.81a.13161","article-title":"New guidelines for reduction of blood cholesterol: was it worth the wait?","volume":"81","author":"Raymond","year":"2014","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.jacl.2018.04.007_bib27","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2018.04.007_bib28","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid lowering therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2018.04.007_bib29","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2018.04.007_bib30","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2018.04.007_bib31","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.jacl.2018.04.007_bib32","author":"U. S. Food and Drug Administration"},{"key":"10.1016\/j.jacl.2018.04.007_bib33","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jacc.2014.09.088","article-title":"Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease","volume":"65","author":"Rosenson","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2018.04.007_bib34","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.amjcard.2015.11.035","article-title":"A US claims-based analysis of real-world lipid-lowering treatment patterns in patients with high cardiovascular disease risk or previous coronary event","volume":"117","author":"Quek","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2018.04.007_bib35","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.atherosclerosis.2016.01.018","article-title":"Lipid-lowering drug therapy in patients with coronary heart disease in 24 countries: findings from the EUROASPIRE IV survey","volume":"246","author":"Reiner","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2018.04.007_bib36","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ahj.2016.07.024","article-title":"Impact of the 2013 American College of Cardiology\/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke","volume":"181","author":"Valentino","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2018.04.007_bib37","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1016\/j.jacc.2017.03.585","article-title":"Trends in use of high-intensity statin therapy after myocardial infarction, 2011 to 2014","volume":"69","author":"Rosenson","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2018.04.007_bib38","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jacl.2014.12.009","article-title":"Updated cholesterol guidelines and intensity of statin","volume":"9","author":"Nguyen","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2018.04.007_bib39","doi-asserted-by":"crossref","first-page":"685","DOI":"10.18553\/jmcp.2016.22.6.685","article-title":"Patterns of statin use in a real-world population of patients at high cardiovascular risk","volume":"22","author":"Lin","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jacl.2018.04.007_bib40","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.2146\/ajhp160050","article-title":"Evaluation of adherence to current guidelines for the treatment of hyperlipidemia in adults in an outpatient setting","volume":"73","author":"Ng","year":"2016","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jacl.2018.04.007_bib41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.7812\/TPP\/11-148","article-title":"Out-of-plan pharmacy use by members of a managed care organization","volume":"16","author":"Delate","year":"2012","journal-title":"Perm J"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287418302058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287418302058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T07:38:56Z","timestamp":1532504336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287418302058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S1933287418302058"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2018.04.007","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in high-intensity statin use and low-density lipoprotein cholesterol control among patients enrolled in a clinical pharmacy cardiac risk service","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2018.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 National Lipid Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}